Tuesday, June 20, 2017

Back To Matters Merck: Dr. Gerberding Elected, At BIO...

We now return to some Merck-focused (people) reporting. The slow summer news cycle appears to be in full effect, this languid June morning -- and I'll not comment on any super-secret, largely meaningless and illusory Senate bill rumors. I just. . . won't.

So, instead -- I will laud Dr. Gerberding, now the elected Board Secretary of trade group BIO (and a member of the board of directors of NASDAQ traded Cerner, a health information technology company) -- well done! [My December 2014 backgrounder on her portfolio of increasing responsibilities, while at Kenilworth, here.]

Here's the BIO press release -- and a bit:

. . . .BIO is pleased to announce the election of John Maraganore, Ph.D., Chief Executive Officer, Alnylam Pharmaceuticals, Inc., as the new Chair of its Board of Directors for the 2017-2018 term, and the election of Julie Gerberding, Executive Vice President for Strategic Communications, Global Public Policy & Population Health & Chief Patient Officer, Merck, as its new Board Secretary. . . .

As I say -- our congrats go out to this fine bio-sciences leader (with deep history in the vaccines arena)! Onward.


No comments: